What is it about?
The aim of the study was to evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) drug dapoxetine in delaying ejaculation in patients with premature ejaculation (PE).
Featured Image
Photo by Diego Passadori on Unsplash
Why is it important?
The prevalence of PE is reported as being between 22 and 38% of adult male population. The World Health Organization (WHO) includes the right to sexual health among its fundamental rights for an individual. There should be ‘a freedom from organic disorders, disease, and deficiencies that interfere with sexual and reproductive freedom.
Perspectives
In some cases most of studies in favor of a drug have been performed by same researchers. Dapoxetine gave chronically improved latencies over baseline. However, even at 60 mg, the latencies were still o2 min in most of the patients. We doubt whether greater than this dose is suitable for large-scale use. FDA did not approve dapoxetine as treatment of choice for premature ejaculation.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study, Neuropsychopharmacology, July 2007, Springer Science + Business Media,
DOI: 10.1038/sj.npp.1301500.
You can read the full text:
Resources
Contributors
The following have contributed to this page
